<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27793204</article-id><article-id pub-id-type="pmc">5084417</article-id><article-id pub-id-type="publisher-id">1648</article-id><article-id pub-id-type="doi">10.1186/s13063-016-1648-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>High-dose intravenously administered iron versus orally administered iron in blood donors with iron deficiency: study protocol for a randomised, controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Macher</surname><given-names>Susanne</given-names></name><address><email>susanne.macher@klinikum-graz.at</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Drexler</surname><given-names>Camilla</given-names></name><address><email>camilla.drexler@klinikum-graz.at</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lindenau</surname><given-names>Ines</given-names></name><address><email>ines.lindenau@stud.medunigraz.at</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sareban</surname><given-names>Nazanin</given-names></name><address><email>nazanin.sareban@klinikum-graz.at</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schlenke</surname><given-names>Peter</given-names></name><address><email>peter.schlenke@medunigraz.at</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Amrein</surname><given-names>Karin</given-names></name><address><phone>0316 385 80798</phone><email>karin.amrein@medunigraz.at</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria </aff><aff id="Aff2"><label>2</label>Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>17</volume><elocation-id>527</elocation-id><history><date date-type="received"><day>12</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>7</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>About 2&#x02013;3&#x000a0;% of the population participates in blood donation programmes. Each whole blood donation or ten apheresis donations cause a loss of 200&#x02013;250&#x000a0;mg of iron. As a result, one of the most common risks of regular blood donors is iron deficiency. Although this has been known for decades, in most countries, iron status is currently not assessed or treated in this population. Premenopausal women are particularly affected, as they have lower iron reserves and higher daily requirements. Besides anaemia, iron deficiency may lead to fatigue and impaired cognitive and physical performance. Current iron preparations for intravenous administration are well tolerated and allow for application of large doses up to 1&#x000a0;g in one visit. Our hypothesis is that in blood donors with iron deficiency, intravenously administered iron is more efficient and as safe as oral iron supplementation. Since anaemia is one of the most frequent reasons for permanent or intermittent donor deferral, maintaining an iron-replete donor pool may help to prevent shortages in blood supply and to avoid iron deficiency-related comorbidities.</p></sec><sec><title>Methods/design</title><p>In this randomised clinical trial we include male and female blood donors aged &#x02265;18 and &#x02264;65&#x000a0;years with a ferritin value of &#x02264;30&#x000a0;ng/ml. Stratified by gender, participants are randomized with a web-based randomisation tool in a 1:1 ratio to either 1&#x000a0;g of intravenously administered ferric carboxymaltose or 10&#x000a0;g of iron fumarate supplements at one to two daily doses of 100&#x000a0;mg each. Eight to 12&#x000a0;weeks after the first visit, iron status, blood count and symptoms are assessed in both groups. The primary endpoint is the difference in transferrin saturation (%) following the intervention between both groups. Secondary endpoints include other parameters of iron metabolism and red blood cell count, the number of patients with drug-related adverse events, and subjective symptoms including those of the restless legs syndrome, quality of life, and fatigue.</p></sec><sec><title>Discussion</title><p>Iron supplementation administered intravenously in non-anaemic but iron-deficient blood donors could represent an effective strategy to protect blood donors from comorbidities related with iron deficiency and therefore improve blood donor wellbeing. Furthermore, iron supplementation will help to maintain an iron-replete blood donor pool.</p></sec><sec><title>Trial registration</title><p>EudraCT: 2013-000327-14, Clinical Trials Identifier: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT01787526?term=NCT01787526&#x00026;rank=1">NCT01787526</ext-link>. Registered on 6 February 2013.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13063-016-1648-y) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Blood donation</kwd><kwd>Donor safety</kwd><kwd>Intravenous iron</kwd><kwd>Iron carboxymaltose</kwd><kwd>Iron deficiency</kwd><kwd>Randomised controlled trial</kwd></kwd-group><funding-group><award-group><funding-source><institution>Vifor Pharma (Austria)</institution></funding-source></award-group><award-group><funding-source><institution>G.L. Pharma</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Iron deficiency is possibly the most prevalent nutritional deficiency worldwide, but guidelines for its diagnosis and treatment vary in their suggestions [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The largest part of iron is bound to haemoglobin in red blood cells [<xref ref-type="bibr" rid="CR1">1</xref>]. Each whole blood donation (plus additional samples for testing) causes an iron loss of 200 to 300&#x000a0;mg [<xref ref-type="bibr" rid="CR3">3</xref>]. Therefore, iron deficiency is prevalent among healthy blood donors, who represent up to 2&#x02013;3&#x000a0;% of the population [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Contributing risk factors for iron deficiency include donation frequency, low body weight, and female gender [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Traditionally, safety issues in transfusion medicine have been concentrating on product quality and patient safety. However, there is still room for optimizing donor care [<xref ref-type="bibr" rid="CR11">11</xref>]. In Austria, the maximal annual donation frequency for whole blood donations is 4 times for premenopausal women, 5 times for postmenopausal women and 6 times for men. The maximal annual donation frequency for platelet apheresis is 26 times and for plasmapheresis 50 times [<xref ref-type="bibr" rid="CR12">12</xref>]. Recently, it has been shown that without iron supplementation, whole blood donors do not recover their predonation hemoglobin and iron status within 6&#x000a0;months [<xref ref-type="bibr" rid="CR13">13</xref>]. Iron depletion in blood donors has been recognized for decades [<xref ref-type="bibr" rid="CR14">14</xref>], and anaemia is routinely assessed by point-of-care haemoglobin devices, but iron status is not. Therefore, non-anaemic iron-deficient donors may not be identified, as iron deficiency may lead to subtle and unspecific symptoms [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>Several trials have evaluated different regimens of iron supplementation in blood donors and demonstrated good treatment efficacy in improving iron status [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. However, many iron-deficient blood donors may need to permanently take oral iron if they continue to donate frequently, since it typically takes 2&#x02013;3 months to correct iron deficiency, which is the minimal time interval between whole blood donations. High-dose iron preparations for intravenous administration have become available which allow for the application of a large dose of 1000&#x000a0;mg in one visit, correcting iron deficiency in many individuals with a single infusion [<xref ref-type="bibr" rid="CR25">25</xref>]. To our knowledge, only two interventional trials using high-dose iron intravenous administration have been performed in blood donors, but only in one study was iron deficiency required for inclusion [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Currently, intravenous iron is not routinely accessible to iron-deficient blood donors, and there are no studies that have compared intravenously administered iron to oral iron supplements in this setting. In our study, we aim to establish that intravenous iron is feasible for correction of iatrogenic iron deficiency in blood donors. When costs and logistical impediments are overcome, this could be a one-stop approach if intravenous iron is given immediately after donation through the available venous access.</p><p>The potential risks related to iron therapy include the masking of other causes of iron deficiency, iron overload in unrecognized hemochromatosis, and drug-related adverse effects. Results from interventional trials in other settings indicate that severe drug reactions of oral and intravenous iron are rare, and that gastrointestinal side effects are experienced less often with intravenously administered iron than with oral iron supplements [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. However, anaphylactic reactions have been described in the intravenous administration of iron [<xref ref-type="bibr" rid="CR29">29</xref>]. A novel, frequent adverse effect after the intravenous infusion of iron and more frequently after ferric carboxymaltose infusion is hypophosphatemia, which may be severe and can lead to profound weakness and even osteomalacia [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>].</p><sec id="Sec2"><title>Aims and hypothesis of the study</title><p>This study will assess the efficacy, safety, and feasibility of intravenous infusion of high-dose iron in blood donors with iron deficiency by comparing intravenously administered ferric carboxymaltose with oral iron fumarate supplements.</p><p>Our hypothesis is that 1&#x000a0;g of intravenously infused ferric carboxymaltose will improve the iron status of blood donors with iron deficiency more efficiently compared to a comparable dose of oral iron supplements (10&#x000a0;g assuming a 10&#x000a0;% resorption rate, given over 8&#x02013;12 weeks).</p></sec></sec><sec id="Sec3"><title>Methods/design</title><p>A SPIRIT checklist is available online for this manuscript (Additional file <xref rid="MOESM1" ref-type="media">1</xref>).</p><sec id="Sec4"><title>Study design</title><p>This is a prospective, randomised, clinical trial. The study population consists of healthy adults, including male and female whole blood and platelet apheresis donors with iron deficiency (ferritin&#x02009;&#x02264;&#x02009;30&#x000a0;ng/ml).</p></sec><sec id="Sec5"><title>Participants</title><sec id="Sec6"><title>Inclusion criteria</title><p>The inclusion criteria are as follows:<list list-type="bullet"><list-item><p>Age&#x02009;&#x02265;&#x02009;18&#x000a0;years and&#x02009;&#x02264;&#x02009;65&#x000a0;years</p></list-item><list-item><p>Iron deficiency (ferritin &#x02264;30&#x000a0;ng/ml at screening &#x02014; usually before blood donation)</p></list-item><list-item><p>Fulfilment of the Austrian criteria for blood donation</p></list-item></list>
</p></sec><sec id="Sec7"><title>Exclusion criteria</title><p>The exclusion criteria are as follows:<list list-type="bullet"><list-item><p>Known haemochromatosis</p></list-item><list-item><p>Acute infection</p></list-item><list-item><p>Pregnancy or lactation</p></list-item><list-item><p>History of anaphylaxis to intravenous infusion of iron or other substances</p></list-item><list-item><p>Signs or symptoms suggestive of acute or chronic gastrointestinal or excessive gynaecological bleeding</p></list-item></list>
</p></sec></sec><sec id="Sec8"><title>Study drugs/intervention</title><p>The study drugs used in the intervention are:<list list-type="bullet"><list-item><p>
<bold>High-dose (1000&#x000a0;mg) intravenous infusions of iron</bold> (ferric carboxymaltose, Ferinject &#x000ae;, manufacturer Vifor Pharma, Austria) or</p></list-item><list-item><p>
<bold>Oral supplements of iron</bold> (iron fumarate, Ferretab&#x000ae;, manufacturer Gerot Lannach, Austria) in a corresponding estimated dose of &#x0003e;10.000&#x000a0;mg (assuming an absorption of 10&#x000a0;%, 100 capsules of 152&#x000a0;mg iron fumarate each) taken over 8&#x02013;12 weeks. Participants are advised to take tablets in the morning with orange or lemon juice.</p></list-item></list>
</p></sec><sec id="Sec9"><title>Outcomes</title><sec id="Sec10"><title>Primary endpoint</title><p>
<list list-type="bullet"><list-item><p>The primary endpoint is the difference in transferrin saturation (%) at visit 1 between the high-dose intravenous infusion and the oral iron supplement group</p></list-item></list>
</p></sec><sec id="Sec11"><title>Secondary objectives</title><p>The secondary objectives are:<list list-type="bullet"><list-item><p>Other parameters of iron metabolism, red blood cell count including the percentage of participants with a normal (gender-specific) haemoglobin at visit 1 (group comparison) and further parameters (e.g. phosphate)</p></list-item><list-item><p>Symptoms including those of restless legs syndrome, quality of life, fatigue</p></list-item><list-item><p>Comparison of the two treatments regarding the incidence and severity of adverse events, tolerance, and compliance</p></list-item></list>
</p></sec></sec><sec id="Sec12"><title>Methods of procedure</title><p>A flow chart of the study procedure is given in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The total study duration for each patient will be 8&#x02013;12 weeks. Based on previous experiences in the recruitment of blood donors for observational studies, we aim to include two study participants per week. Thus, the total recruitment period is estimated to last for 21&#x02013;24 months and the total active study duration will be 26&#x000a0;months. Recruitment started in June 2014 and was completed in June 2016. At the time of revision, all 176 participants (172 according to the sample size calculation plus 4 dropouts) have been included.<fig id="Fig1"><label>Fig. 1</label><caption><p>Study flow chart</p></caption><graphic xlink:href="13063_2016_1648_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec13"><title>Study duration for the individual participant</title><p>The active treatment period for each participant is 8&#x02013;12 weeks.</p></sec><sec id="Sec14"><title>Screening</title><p>Typically after a regular whole blood or platelet apheresis donation, ferritin is measured from the remaining serum for routine infectious disease testing. The regular written informed consent for blood donation covers the additional ferritin analysis. Donors with a serum ferritin &#x02264;30&#x000a0;ng/ml will then be invited by telephone to participate in the study.</p></sec><sec id="Sec15"><title>Visit 0 including randomization procedure (4&#x02013;6 weeks after blood donation)</title><p>Donors willing to participate are requested to visit the Apheresis Unit of the Department of Blood Group Serology and Transfusion Medicine. After giving written informed consent, checking inclusion/exclusion criteria and performing a urine pregnancy test in premenopausal females, a case report form (CRF) is filled out by the donor.</p><p>The CRF includes questions on the following aspects:<list list-type="bullet"><list-item><p>History of blood donation (total number, time)</p></list-item><list-item><p>History of anaemia</p></list-item><list-item><p>Symptoms of fatigue</p></list-item><list-item><p>Subjective physical and cognitive performance including self-reported physical activity and hours worked per week</p></list-item><list-item><p>Symptoms of depression or lethargy</p></list-item><list-item><p>Trophic changes of fingernails or hair</p></list-item><list-item><p>Fatigue induced by blood donation</p></list-item><list-item><p>Symptoms of restless legs syndrome</p></list-item></list>
</p><sec id="Sec16"><title>Randomization procedure</title><p>Each participant will be randomized in a 1:1 ratio (stratified by gender) to either high-dose parenterally infused iron or oral iron supplements using a web-based randomisation tool (<ext-link ext-link-type="uri" xlink:href="http://www.randomizer.at">http://www.randomizer.at</ext-link>). Good clinical practice (GCP) compliance of this software was confirmed by the Austrian Agency for Health and Food Safety (AGES).</p></sec><sec id="Sec17"><title>Blood samples</title><p>A blood sample (~30&#x000a0;ml) is drawn from all participants, in case of randomisation to parenterally infused iron from a venous access placed for the application of the intravenously administered iron. Some parameters may be measured after the end of the study from frozen blood specimens stored at &#x02212;70&#x000a0;&#x000b0;C.</p></sec><sec id="Sec18"><title>Faecal occult blood tests</title><p>To assess occult gastrointestinal bleeding, all participants are asked to perform three faecal occult blood tests at home in the time between visit 0 and visit 1.</p></sec><sec id="Sec19"><title>Medication</title><p>According to the randomization, either 100 tablets of oral iron supplements are handed out to the participant or iron is administered intravenously by the study investigators in the presence of a nurse.</p><p>For oral iron supplements, all participants receive an exact schedule for tablet intake together with clear instructions according to the package leaflet: we suggest to take 10 tablets per week (3&#x000a0;days 2 tablets, 4&#x000a0;days 1 tablet) and to take the tablets with orange juice.</p><p>Iron is administered intravenously to the participants in a bed in a separate room of the Apheresis Unit of the University Clinic of Blood Group Serology and Transfusion Medicine. Iron is infused intravenously over 30&#x000a0;minutes or more over a dedicated peripheral line. A standard operating procedure involving the resuscitation outreach team of the Department of Anesthesiology has been developed, and basic emergency equipment is available at all times.</p></sec></sec><sec id="Sec20"><title>Visit 1 (8&#x02013;12 weeks after visit 0)</title><p>A treatment period of 8&#x02013;12 weeks is chosen because the administration of 8&#x02013;13 doses of 100&#x000a0;mg iron in one week is feasible and it also matches the typical donation interval. Furthermore, serum ferritin levels are falsely high when analysed &#x02264;6&#x000a0;weeks after intravenous infusion of iron.</p><p>A CRF including assessment of compliance is completed by the donor, and a blood sample (~30&#x000a0;ml) is drawn. All results are summarized in a written report for the study participants and sent by regular mail.</p><p>The CRF at visit 1 will additionally include questions on the following aspects:<list list-type="bullet"><list-item><p>Information on any relevant adverse events, serious adverse events and adverse drug reactions</p></list-item><list-item><p>Compliance with oral study medication intake (self-reported; the participants are also asked to bring back all leftover medication)</p></list-item></list>
</p></sec><sec id="Sec21"><title>Statistical aspects</title><sec id="Sec22"><title>Sample size justification</title><p>The sample size calculation was performed by the Department of Medical Informatics, Statistics and Documentation of the Medical University of Graz. Using a two-group <italic>t</italic> test with a 0.05 two-sided significance level, a sample size of 86 participants in each group will have 90&#x000a0;% power to detect a difference in mean of 8&#x000a0;% in transferrin saturation (estimating a post-treatment transferrin saturation of 28&#x000a0;% and 20&#x000a0;% in the high-dose intravenous iron group and oral iron group, respectively, based on results by a similar treatment regimen in otherwise healthy women with postpartum anaemia [<xref ref-type="bibr" rid="CR34">34</xref>]). Allowing for a dropout of 14&#x000a0;%, originally 200 participants were planned to be enrolled in the study. As the actual dropout rate was substantially lower (&#x0003c;3&#x000a0;%), the study will be terminated after complete study participation of 172 participants plus the number of dropouts.</p></sec><sec id="Sec23"><title>Statistical procedures</title><p>Statistical analyses of the results will be performed using the intention-to-treat and the per-protocol principles. All study participants who are randomised and included into the study will be analysed whether they take their study medication for the entire term (oral iron) or not or whether or not they miss the follow-up visit (visit 1). All primary and secondary outcome measures will be analysed and checked for normal distribution of the results. If there is a normal distribution of laboratory results, they will be analysed by the two-sided <italic>t</italic> test; if there is not a normal distribution they will be analysed by non-parametric tests like the Wilcoxon test for related samples or the Mann-Whitney U test for comparison of independent samples. The significance level will be set to <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. Data will be presented as mean&#x02009;&#x000b1;&#x02009;standard deviation or median (interquartile ranges) as appropriate. For missing data, no imputation will be performed. A statistical evaluation will be performed using the software program SPSS for Windows (IBM SPSS Inc., Chicago, IL, USA).</p><p>A predefined subgroup analysis will separately analyse participants with a baseline ferritin of &#x02264;15&#x000a0;ng/ml. The Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, will maintain responsibility for the final trial dataset.</p></sec></sec><sec id="Sec24"><title>Data and safety monitoring</title><p>All laboratory analyses are stored on password-protected secure servers and will only be accessible for authorized individuals from the Medical University of Graz. Clinical data are collected through paper-based CRFs. The CRFs are confidential documents and held securely at the Department of Blood Group Serology and Transfusion Medicine. Each participant is assigned a trial identity code number to anonymize documented CRF data.</p><p>In the CRF of the follow-up visit (visit 1), the participants are asked for possible drug-related adverse events. Furthermore, all participants are requested to promptly report possible adverse events by telephone. The study participants receive telephone contact numbers from the study team at the time of inclusion (visit 0).</p></sec><sec id="Sec25"><title>Subject recruitment</title><p>In Styria, annually about 60.000 units of whole blood are collected at mobile and stationary locations by the Red Cross and further processed to packed red blood cell concentrates, pooled platelet concentrates and fresh frozen plasma at the Department of Blood Group Serology and Transfusion Medicine of the Medical University of Graz. Approximately 1200 single donor platelet apheresis collections are performed in our department per year. A number of different commercial plasma collection centres in the region offer the opportunity to donate apheresis plasma.</p><p>Depending on the region of residence, we estimate that 5000 to 10,000 donors are potential participants of this study. Of those, 1000 to 2000 may fulfil the inclusion and exclusion criteria; thus, we need to recruit 10&#x02013;20&#x000a0;% of all potential participants. We aim to recruit two blood donors per week for this trial.</p><p>The University Hospital of Graz (&#x0201c;LKH-Universit&#x000e4;tsklinikum Graz&#x0201d;) is a large tertiary care facility with 7200 employees. It is the teaching hospital for one of the three public Medical Universities in Austria. The catchment area covers the entire southeast of Austria (approximately 2 million people). Currently 1413 beds at general wards and 112 intensive care unit (ICU) beds are available. Each year, approximately 80,000 patients are treated as inpatients and 440,000 as outpatients.</p></sec><sec id="Sec26"><title>Specific gender relevance of the project</title><p>Adverse reactions related to blood donation are more common in females, which is one of the major reasons why more men become regular donors [<xref ref-type="bibr" rid="CR35">35</xref>]. In particular, iron deficiency caused by blood donation is highly prevalent in premenopausal female donors because of lower blood volume, higher requirements, and greater losses during menstrual bleeding, pregnancies, birth, and lactation [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. The estimated iron loss from one whole blood donation corresponds to approximately 10&#x000a0;% of total body iron and 66&#x02013;97&#x000a0;% of the total iron stores of a premenopausal woman [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p><p>More importantly, unrecognized and therefore untreated iron deficiency has been linked to adverse pregnancy outcomes such as preterm delivery and lower weight babies [<xref ref-type="bibr" rid="CR40">40</xref>]. Particularly in the subgroup of premenopausal females, a regular evaluation of donor iron status should be considered or the donation intervals prolonged.</p><sec id="Sec27"><title>Study participation for premenopausal women</title><p>There are no data available on foetal toxicity of ferric carboxymaltose, so the application of this drug during the early stages of pregnancy is contraindicated. Therefore, women of childbearing age are only allowed to participate in this trial when pregnancy has been excluded by urinary &#x003b2;-HCG testing at the beginning of the study and is repeated by the participants in the intervention phase. Lactating women are excluded from blood donation and therefore are also not targeted in this study.</p></sec></sec><sec id="Sec28"><title>Ethical aspects</title><p>The approval of the institutional ethical committee was given in June 2013 (EK 25&#x02013;345 ex 12/13) and has been renewed yearly.</p></sec><sec id="Sec29"><title>Registration at clinical trials</title><p>This trial was registered at ClinicalTrials.gov in February 2013 (Clinical Trials Identifier: NCT01787526).</p></sec></sec><sec id="Sec30"><title>Discussion</title><p>Iron deficiency anaemia occurs when iron stores have been consumed [<xref ref-type="bibr" rid="CR1">1</xref>]. Before establishment of anaemia, iron deficiency may have other, more subtle and unspecific adverse effects on an individual such as decreased physical and cognitive performance [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Since iron is an important element in many enzymes, deficiency may affect various cellular processes like DNA synthesis [<xref ref-type="bibr" rid="CR43">43</xref>], mitochondrial energy metabolism [<xref ref-type="bibr" rid="CR44">44</xref>], and the immune system [<xref ref-type="bibr" rid="CR45">45</xref>]. Therefore, blood donation establishments should focus on donors at risk for iatrogenic iron deficiency without anaemia and develop strategies for its prevention. Although the benefit of iron therapy in subjects without anaemia remains controversial, mainly due to a lack of large randomised clinical trials for truly deficient subjects, a few studies have reported interesting results. For example, iron supplementation reduced unexplained fatigue in otherwise healthy women with iron deficiency and improved verbal learning and memory in adolescent girls [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Iron deficiency has additionally been found to be associated with restless legs syndrome, and iron therapy improved symptoms significantly in blood donors [<xref ref-type="bibr" rid="CR47">47</xref>]. Recently, it was shown that the recovery of blood donors&#x02019; iron stores receiving oral iron supplementation after blood donation took a median of 76&#x000a0;days compared to a median recovery time of longer than 168&#x000a0;days for study participants not taking iron [<xref ref-type="bibr" rid="CR13">13</xref>], also questioning the current relatively short donation intervals of 2&#x02013;3 months.</p><p>So far, no randomised controlled trial has compared high-dose intravenous iron to oral iron supplementation in blood donors with iron deficiency. Intravenous iron may be an excellent option in this setting. If our study can establish that intravenous iron is feasible in blood donors and the substantial impediments like costs and logistics can be overcome, high-dose intravenously infused iron given immediately after whole blood or apheresis donation through the present venous access could be a very efficient way for correction and/or prevention of iatrogenic iron deficiency. Such an approach could protect blood donors from symptoms related to iron deficiency and help to maintain an iron-replete blood donor pool.</p><sec id="Sec31"><title>Trial status at the time of initial manuscript submission</title><p>Recruitment for this trial is ongoing.</p></sec></sec></body><back><app-group><app id="App1"><sec id="Sec32"><title>Additional file</title><p>
<media position="anchor" xlink:href="13063_2016_1648_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1:</label><caption><p>SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*. (DOCX 63 kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>AGES</term><def><p>Austrian Agency for Health and Food Safety</p></def></def-item><def-item><term>CRF</term><def><p>Case report form</p></def></def-item><def-item><term>GCP</term><def><p>Good clinical practice</p></def></def-item><def-item><term>ICU</term><def><p>Intensive care unit</p></def></def-item><def-item><term>IV</term><def><p>Intravenous</p></def></def-item><def-item><term>PO</term><def><p>Peroral</p></def></def-item><def-item><term>&#x003b2;-HCG</term><def><p>Beta-human chorionic gonadotropin</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We appreciate the support of the Apheresis Unit under the lead of S. Sipurzynski and M. Stepanek. We further thank T. Stojakovic for scientific support concerning laboratory data and M. Schr&#x000f6;ck, C. Reinprecht and M. Moritz for operative support. We are grateful for the statistical support of the Department of Medical Informatics, Statistics and Documentation of the Medical University of Graz for sample size calculation.</p><sec id="FPar1"><title>Funding</title><p>The trial is funded by the Medical University of Graz and Vifor Pharma and received the oral study drug from GL Pharma.</p></sec><sec id="FPar2"><title>Authors&#x02019; contributions</title><p>KA, CD and NS designed the study; SM and PS contributed to the study design and screening procedure; KA secured funding for the project; SM, CD and IL form the ongoing trial management group with advice from KA and PS; SM, CD and KA drafted the manuscript. All authors commented upon the amended drafts and have approved the final manuscript.</p></sec><sec id="FPar3"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar4"><title>Ethics approval and consent to participate</title><p>The study is carried out according to GCP guidelines and conforms to the Declaration of Helsinki. The study has been approved by the Austrian Agency for Health and Food Safety (AGES) and by the Ethical Committee of the Medical University of Graz. All participants give written informed consent.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>NC</given-names></name></person-group><article-title>Disorders of iron metabolism</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><issue>26</issue><fpage>1986</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1056/NEJM199912233412607</pub-id><pub-id pub-id-type="pmid">10607817</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peyrin-Biroulet</surname><given-names>L</given-names></name><name><surname>Williet</surname><given-names>N</given-names></name><name><surname>Cacoub</surname><given-names>P</given-names></name></person-group><article-title>Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review</article-title><source>Am J Clin Nutr</source><year>2015</year><volume>102</volume><issue>6</issue><fpage>1585</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.3945/ajcn.114.103366</pub-id><pub-id pub-id-type="pmid">26561626</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>ME</given-names></name><name><surname>Crosby</surname><given-names>WH</given-names></name><name><surname>Jacobs</surname><given-names>A</given-names></name><name><surname>Kaltwasser</surname><given-names>JP</given-names></name><name><surname>Nusbacher</surname><given-names>J</given-names></name></person-group><article-title>The Hippocratian principle of &#x02018;primum nil nocere&#x02019; demands that the metabolic state of a donor should be normalized prior to a subsequent donation of blood or plasma. How much blood, relative to his body weight, can a donor give over a certain period, without a continuous deviation of iron metabolism in the direction of iron deficiency?</article-title><source>Vox Sang</source><year>1981</year><volume>41</volume><issue>5&#x02013;6</issue><fpage>336</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">7324448</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semmelrock</surname><given-names>MJ</given-names></name><name><surname>Raggam</surname><given-names>RB</given-names></name><name><surname>Amrein</surname><given-names>K</given-names></name><name><surname>Avian</surname><given-names>A</given-names></name><name><surname>Schallmoser</surname><given-names>K</given-names></name><name><surname>Lanzer</surname><given-names>G</given-names></name><etal/></person-group><article-title>Reticulocyte hemoglobin content allows early and reliable detection of functional iron deficiency in blood donors</article-title><source>Clin Chim Acta</source><year>2012</year><volume>413</volume><issue>7&#x02013;8</issue><fpage>678</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2011.12.006</pub-id><pub-id pub-id-type="pmid">22212625</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>TL</given-names></name></person-group><article-title>Iron, iron everywhere but not enough to donate</article-title><source>Transfusion</source><year>2002</year><volume>42</volume><issue>6</issue><fpage>664</fpage><pub-id pub-id-type="doi">10.1046/j.1537-2995.2002.00121.x</pub-id><pub-id pub-id-type="pmid">12147015</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>TL</given-names></name><name><surname>Garry</surname><given-names>PJ</given-names></name><name><surname>Hooper</surname><given-names>EM</given-names></name></person-group><article-title>Iron stores in blood donors</article-title><source>JAMA</source><year>1981</year><volume>245</volume><issue>20</issue><fpage>2038</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1001/jama.1981.03310450030018</pub-id><pub-id pub-id-type="pmid">7230400</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brittenham</surname><given-names>GM</given-names></name></person-group><article-title>Iron deficiency in whole blood donors</article-title><source>Transfusion</source><year>2011</year><volume>51</volume><issue>3</issue><fpage>458</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2011.03062.x</pub-id><pub-id pub-id-type="pmid">21388389</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cable</surname><given-names>RG</given-names></name><name><surname>Glynn</surname><given-names>SA</given-names></name><name><surname>Kiss</surname><given-names>JE</given-names></name><name><surname>Mast</surname><given-names>AE</given-names></name><name><surname>Steele</surname><given-names>WR</given-names></name><name><surname>Murphy</surname><given-names>EL</given-names></name><etal/></person-group><article-title>Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study</article-title><source>Transfusion</source><year>2011</year><volume>51</volume><issue>3</issue><fpage>511</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2010.02865.x</pub-id><pub-id pub-id-type="pmid">20804527</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finch</surname><given-names>CA</given-names></name><name><surname>Cook</surname><given-names>JD</given-names></name><name><surname>Labbe</surname><given-names>RF</given-names></name><name><surname>Culala</surname><given-names>M</given-names></name></person-group><article-title>Effect of blood donation on iron stores as evaluated by serum ferritin</article-title><source>Blood</source><year>1977</year><volume>50</volume><issue>3</issue><fpage>441</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">884321</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baart</surname><given-names>AM</given-names></name><name><surname>van Noord</surname><given-names>PA</given-names></name><name><surname>Vergouwe</surname><given-names>Y</given-names></name><name><surname>Moons</surname><given-names>KG</given-names></name><name><surname>Swinkels</surname><given-names>DW</given-names></name><name><surname>Wiegerinck</surname><given-names>ET</given-names></name><etal/></person-group><article-title>High prevalence of subclinical iron deficiency in whole blood donors not deferred for low hemoglobin</article-title><source>Transfusion</source><year>2013</year><volume>53</volume><issue>8</issue><fpage>1670</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2012.03956.x</pub-id><pub-id pub-id-type="pmid">23176175</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amrein</surname><given-names>K</given-names></name><name><surname>Valentin</surname><given-names>A</given-names></name><name><surname>Lanzer</surname><given-names>G</given-names></name><name><surname>Drexler</surname><given-names>C</given-names></name></person-group><article-title>Adverse events and safety issues in blood donation&#x02014;a comprehensive review</article-title><source>Blood Rev</source><year>2012</year><volume>26</volume><issue>1</issue><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.blre.2011.09.003</pub-id><pub-id pub-id-type="pmid">21996651</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Bundesministerium f&#x000fc;r Arbeit GuS. BGBl. II Nr. 100/1999 in der geltenden Fassung. 1999.</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiss</surname><given-names>JE</given-names></name><name><surname>Brambilla</surname><given-names>D</given-names></name><name><surname>Glynn</surname><given-names>SA</given-names></name><name><surname>Mast</surname><given-names>AE</given-names></name><name><surname>Spencer</surname><given-names>BR</given-names></name><name><surname>Stone</surname><given-names>M</given-names></name><etal/></person-group><article-title>Oral iron supplementation after blood donation: a randomized clinical trial</article-title><source>JAMA</source><year>2015</year><volume>313</volume><issue>6</issue><fpage>575</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.119</pub-id><pub-id pub-id-type="pmid">25668261</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bast</surname><given-names>G</given-names></name><name><surname>Peisker</surname><given-names>H</given-names></name><name><surname>Schumann</surname><given-names>HD</given-names></name></person-group><article-title>Latent disorders caused by iron deficiency in frequent blood donors</article-title><source>Langenbecks Arch Klin Chir Ver Dtsch Z Chir</source><year>1956</year><volume>283</volume><issue>3</issue><fpage>280</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">13386295</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdon</surname><given-names>F</given-names></name><name><surname>Burnand</surname><given-names>B</given-names></name><name><surname>Stubi</surname><given-names>CL</given-names></name><name><surname>Bonard</surname><given-names>C</given-names></name><name><surname>Graff</surname><given-names>M</given-names></name><name><surname>Michaud</surname><given-names>A</given-names></name><etal/></person-group><article-title>Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial</article-title><source>BMJ</source><year>2003</year><volume>326</volume><issue>7399</issue><fpage>1124</fpage><pub-id pub-id-type="doi">10.1136/bmj.326.7399.1124</pub-id><pub-id pub-id-type="pmid">12763985</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birgegard</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>K</given-names></name><name><surname>Ulfberg</surname><given-names>J</given-names></name></person-group><article-title>High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron</article-title><source>Vox Sang</source><year>2010</year><volume>99</volume><issue>4</issue><fpage>354</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1423-0410.2010.01368.x</pub-id><pub-id pub-id-type="pmid">20598107</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pittori</surname><given-names>C</given-names></name><name><surname>Buser</surname><given-names>A</given-names></name><name><surname>Gasser</surname><given-names>UE</given-names></name><name><surname>Sigle</surname><given-names>J</given-names></name><name><surname>Job</surname><given-names>S</given-names></name><name><surname>Ruesch</surname><given-names>M</given-names></name><etal/></person-group><article-title>A pilot iron substitution programme in female blood donors with iron deficiency without anaemia</article-title><source>Vox Sang</source><year>2011</year><volume>100</volume><issue>3</issue><fpage>303</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1111/j.1423-0410.2010.01427.x</pub-id><pub-id pub-id-type="pmid">21091697</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radtke</surname><given-names>H</given-names></name><name><surname>Mayer</surname><given-names>B</given-names></name><name><surname>Rocker</surname><given-names>L</given-names></name><name><surname>Salama</surname><given-names>A</given-names></name><name><surname>Kiesewetter</surname><given-names>H</given-names></name></person-group><article-title>Iron supplementation and 2-unit red blood cell apheresis: a randomized, double-blind, placebo-controlled study</article-title><source>Transfusion</source><year>2004</year><volume>44</volume><issue>10</issue><fpage>1463</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2004.04045.x</pub-id><pub-id pub-id-type="pmid">15383019</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radtke</surname><given-names>H</given-names></name><name><surname>Tegtmeier</surname><given-names>J</given-names></name><name><surname>Rocker</surname><given-names>L</given-names></name><name><surname>Salama</surname><given-names>A</given-names></name><name><surname>Kiesewetter</surname><given-names>H</given-names></name></person-group><article-title>Daily doses of 20&#x000a0;mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double-blind, placebo-controlled study</article-title><source>Transfusion</source><year>2004</year><volume>44</volume><issue>10</issue><fpage>1427</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2004.04074.x</pub-id><pub-id pub-id-type="pmid">15383014</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radtke</surname><given-names>H</given-names></name><name><surname>Tegtmeier</surname><given-names>J</given-names></name><name><surname>Rocker</surname><given-names>L</given-names></name><name><surname>Salama</surname><given-names>A</given-names></name><name><surname>Kiesewetter</surname><given-names>H</given-names></name></person-group><article-title>Compensating for iron loss in regular blood donors using ferrous gluconate and ascorbic acid</article-title><source>Transfusion</source><year>2005</year><volume>45</volume><issue>7</issue><fpage>1236</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2005.00183.x</pub-id><pub-id pub-id-type="pmid">15987376</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldvogel</surname><given-names>S</given-names></name><name><surname>Pedrazzini</surname><given-names>B</given-names></name><name><surname>Vaucher</surname><given-names>P</given-names></name><name><surname>Bize</surname><given-names>R</given-names></name><name><surname>Cornuz</surname><given-names>J</given-names></name><name><surname>Tissot</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial</article-title><source>BMC Med</source><year>2012</year><volume>10</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/1741-7015-10-8</pub-id><pub-id pub-id-type="pmid">22272750</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryant</surname><given-names>BJ</given-names></name><name><surname>Yau</surname><given-names>YY</given-names></name><name><surname>Arceo</surname><given-names>SM</given-names></name><name><surname>Daniel-Johnson</surname><given-names>J</given-names></name><name><surname>Hopkins</surname><given-names>JA</given-names></name><name><surname>Leitman</surname><given-names>SF</given-names></name></person-group><article-title>Iron replacement therapy in the routine management of blood donors</article-title><source>Transfusion</source><year>2012</year><volume>52</volume><issue>7</issue><fpage>1566</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2011.03488.x</pub-id><pub-id pub-id-type="pmid">22211316</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnussen</surname><given-names>K</given-names></name><name><surname>Bork</surname><given-names>N</given-names></name><name><surname>Asmussen</surname><given-names>L</given-names></name></person-group><article-title>The effect of a standardized protocol for iron supplementation to blood donors low in hemoglobin concentration</article-title><source>Transfusion</source><year>2008</year><volume>48</volume><issue>4</issue><fpage>749</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2007.01601.x</pub-id><pub-id pub-id-type="pmid">18194390</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnussen</surname><given-names>K</given-names></name><name><surname>Ladelund</surname><given-names>S</given-names></name></person-group><article-title>Handling low hemoglobin and iron deficiency in a blood donor population: 2&#x000a0;years&#x02019; experience</article-title><source>Transfusion</source><year>2015</year><volume>55</volume><issue>10</issue><fpage>2473</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/trf.13152</pub-id><pub-id pub-id-type="pmid">25988343</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>RA</given-names></name><name><surname>Gaskell</surname><given-names>H</given-names></name><name><surname>Rose</surname><given-names>P</given-names></name><name><surname>Allan</surname><given-names>J</given-names></name></person-group><article-title>Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data</article-title><source>BMC Blood Disord</source><year>2011</year><volume>11</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/1471-2326-11-4</pub-id><pub-id pub-id-type="pmid">21942989</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontana</surname><given-names>S</given-names></name><name><surname>J&#x000fc;ni</surname><given-names>P</given-names></name><name><surname>Niederhauser</surname><given-names>C</given-names></name><name><surname>Keller</surname><given-names>P</given-names></name></person-group><article-title>Lack of effectiveness of intravenous iron infusion in healthy blood donors with low ferritin: a double-blind randomized controlled trial</article-title><source>Vox Sang</source><year>2014</year><volume>107</volume><issue>Supplement S1, Abstracts of the 33rd International Congress of the International Society of Blood Transfusion, Seoul, Korea, May 31&#x02013;June 5, 2014</issue><fpage>98</fpage></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekermo</surname><given-names>B</given-names></name><name><surname>Forsberg</surname><given-names>P</given-names></name><name><surname>Schedvin</surname><given-names>G</given-names></name></person-group><article-title>An open, randomised, clinical study of oral versus intravenous iron for iron substitution in blood donors</article-title><source>Transfusion</source><year>2013</year><volume>53</volume><issue>Supplement: Abstract Presentations from the AABB Annual Meeting and CTTXPO, Denver, CO, October 12&#x02013;15, 2013</issue><fpage>36A</fpage></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rognoni</surname><given-names>C</given-names></name><name><surname>Venturini</surname><given-names>S</given-names></name><name><surname>Meregaglia</surname><given-names>M</given-names></name><name><surname>Marmifero</surname><given-names>M</given-names></name><name><surname>Tarricone</surname><given-names>R</given-names></name></person-group><article-title>Efficacy and safety of ferric carboxymaltose and other formulations in iron-deficient patients: a systematic review and network meta-analysis of randomised controlled trials</article-title><source>Clin Drug Investig</source><year>2016</year><volume>36</volume><issue>3</issue><fpage>177</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1007/s40261-015-0361-z</pub-id><pub-id pub-id-type="pmid">26692005</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Graham</surname><given-names>DJ</given-names></name><name><surname>Kane</surname><given-names>RC</given-names></name><name><surname>Xie</surname><given-names>D</given-names></name><name><surname>Wernecke</surname><given-names>M</given-names></name><name><surname>Levenson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparative risk of anaphylactic reactions associated with intravenous iron products</article-title><source>JAMA</source><year>2015</year><volume>314</volume><issue>19</issue><fpage>2062</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.15572</pub-id><pub-id pub-id-type="pmid">26575062</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gravesen</surname><given-names>E</given-names></name><name><surname>Hofman-Bang</surname><given-names>J</given-names></name><name><surname>Mace</surname><given-names>ML</given-names></name><name><surname>Lewin</surname><given-names>E</given-names></name><name><surname>Olgaard</surname><given-names>K</given-names></name></person-group><article-title>High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats</article-title><source>BMC Nephrol</source><year>2013</year><volume>14</volume><fpage>281</fpage><pub-id pub-id-type="doi">10.1186/1471-2369-14-281</pub-id><pub-id pub-id-type="pmid">24373521</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>S</given-names></name><name><surname>Vandemergel</surname><given-names>X</given-names></name></person-group><article-title>Intravenous iron administration and hypophosphatemia in clinical practice</article-title><source>Int J Rheumatol</source><year>2015</year><volume>2015</volume><fpage>468675</fpage><pub-id pub-id-type="doi">10.1155/2015/468675</pub-id><pub-id pub-id-type="pmid">26000018</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandemergel</surname><given-names>X</given-names></name><name><surname>Vandergheynst</surname><given-names>F</given-names></name></person-group><article-title>Potentially life-threatening phosphate diabetes induced by ferric carboxymaltose injection: a case report and review of the literature</article-title><source>Case Rep Endocrinol</source><year>2014</year><volume>2014</volume><fpage>843689</fpage><pub-id pub-id-type="pmid">25478250</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Sangros SMJ, Goni GE, Camarero SA, Estebanez EC, Lozano MME. Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy. Rev Esp Med Nucl Imagen Mol. 2016. doi: 10.1016/j.remn.2016.04.006.</mixed-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seid</surname><given-names>MH</given-names></name><name><surname>Derman</surname><given-names>RJ</given-names></name><name><surname>Baker</surname><given-names>JB</given-names></name><name><surname>Banach</surname><given-names>W</given-names></name><name><surname>Goldberg</surname><given-names>C</given-names></name><name><surname>Rogers</surname><given-names>R</given-names></name></person-group><article-title>Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial</article-title><source>Am J Obstet Gynecol</source><year>2008</year><volume>199</volume><issue>4</issue><fpage>435</fpage><pub-id pub-id-type="doi">10.1016/j.ajog.2008.07.046</pub-id><pub-id pub-id-type="pmid">18928998</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bani</surname><given-names>M</given-names></name><name><surname>Giussani</surname><given-names>B</given-names></name></person-group><article-title>Gender differences in giving blood: a review of the literature</article-title><source>Blood Transfus</source><year>2010</year><volume>8</volume><issue>4</issue><fpage>278</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">20967170</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianco</surname><given-names>C</given-names></name><name><surname>Brittenham</surname><given-names>G</given-names></name><name><surname>Gilcher</surname><given-names>RO</given-names></name><name><surname>Gordeuk</surname><given-names>VR</given-names></name><name><surname>Kushner</surname><given-names>JP</given-names></name><name><surname>Sayers</surname><given-names>M</given-names></name><etal/></person-group><article-title>Maintaining iron balance in women blood donors of childbearing age: summary of a workshop</article-title><source>Transfusion</source><year>2002</year><volume>42</volume><issue>6</issue><fpage>798</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1046/j.1537-2995.2002.00103.x</pub-id><pub-id pub-id-type="pmid">12147035</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>B</given-names></name></person-group><article-title>Iron depletion by whole-blood donation harms menstruating females: the current whole-blood-collection paradigm needs to be changed</article-title><source>Transfusion</source><year>2006</year><volume>46</volume><issue>10</issue><fpage>1667</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2006.00969.x</pub-id><pub-id pub-id-type="pmid">17002622</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>JD</given-names></name><name><surname>Skikne</surname><given-names>BS</given-names></name><name><surname>Lynch</surname><given-names>SR</given-names></name><name><surname>Reusser</surname><given-names>ME</given-names></name></person-group><article-title>Estimates of iron sufficiency in the US population</article-title><source>Blood</source><year>1986</year><volume>68</volume><issue>3</issue><fpage>726</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">3742051</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skikne</surname><given-names>B</given-names></name><name><surname>Lynch</surname><given-names>S</given-names></name><name><surname>Borek</surname><given-names>D</given-names></name><name><surname>Cook</surname><given-names>J</given-names></name></person-group><article-title>Iron and blood donation</article-title><source>Clin Haematol</source><year>1984</year><volume>13</volume><issue>1</issue><fpage>271</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">6373083</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholl</surname><given-names>TO</given-names></name><name><surname>Hediger</surname><given-names>ML</given-names></name></person-group><article-title>Anemia and iron-deficiency anemia: compilation of data on pregnancy outcome</article-title><source>Am J Clin Nutr</source><year>1994</year><volume>59</volume><issue>2 Suppl</issue><fpage>492S</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">8304287</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollitt</surname><given-names>E</given-names></name></person-group><article-title>Iron deficiency and cognitive function</article-title><source>Annu Rev Nutr</source><year>1993</year><volume>13</volume><fpage>521</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1146/annurev.nu.13.070193.002513</pub-id><pub-id pub-id-type="pmid">8369157</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>RC</given-names></name><name><surname>Jacobson</surname><given-names>JL</given-names></name><name><surname>Burden</surname><given-names>MJ</given-names></name><name><surname>Armony-Sivan</surname><given-names>R</given-names></name><name><surname>Dodge</surname><given-names>NC</given-names></name><name><surname>Angelilli</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Iron deficiency anemia and cognitive function in infancy</article-title><source>Pediatrics</source><year>2010</year><volume>126</volume><issue>2</issue><fpage>e427</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1542/peds.2009-2097</pub-id><pub-id pub-id-type="pmid">20660551</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furukawa</surname><given-names>T</given-names></name><name><surname>Naitoh</surname><given-names>Y</given-names></name><name><surname>Kohno</surname><given-names>H</given-names></name><name><surname>Tokunaga</surname><given-names>R</given-names></name><name><surname>Taketani</surname><given-names>S</given-names></name></person-group><article-title>Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis</article-title><source>Life Sci</source><year>1992</year><volume>50</volume><issue>26</issue><fpage>2059</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(92)90572-7</pub-id><pub-id pub-id-type="pmid">1608289</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackrell</surname><given-names>BA</given-names></name><name><surname>Maguire</surname><given-names>JJ</given-names></name><name><surname>Dallman</surname><given-names>PR</given-names></name><name><surname>Kearney</surname><given-names>EB</given-names></name></person-group><article-title>Effect of iron deficiency on succinate- and NADH-ubiquinone oxidoreductases in skeletal muscle mitochondria</article-title><source>J Biol Chem</source><year>1984</year><volume>259</volume><issue>16</issue><fpage>10053</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">6432778</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>RJ</given-names></name><name><surname>Crichton</surname><given-names>RR</given-names></name><name><surname>Taylor</surname><given-names>DL</given-names></name><name><surname>Della Corte</surname><given-names>L</given-names></name><name><surname>Srai</surname><given-names>SK</given-names></name><name><surname>Dexter</surname><given-names>DT</given-names></name></person-group><article-title>Iron and the immune system</article-title><source>J Neural Transm (Vienna, Austria: 1996)</source><year>2011</year><volume>118</volume><issue>3</issue><fpage>315</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1007/s00702-010-0479-3</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruner</surname><given-names>AB</given-names></name><name><surname>Joffe</surname><given-names>A</given-names></name><name><surname>Duggan</surname><given-names>AK</given-names></name><name><surname>Casella</surname><given-names>JF</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name></person-group><article-title>Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls</article-title><source>Lancet</source><year>1996</year><volume>348</volume><issue>9033</issue><fpage>992</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(96)02341-0</pub-id><pub-id pub-id-type="pmid">8855856</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulfberg</surname><given-names>J</given-names></name><name><surname>Nystrom</surname><given-names>B</given-names></name></person-group><article-title>Restless legs syndrome in blood donors</article-title><source>Sleep Med</source><year>2004</year><volume>5</volume><issue>2</issue><fpage>115</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2003.09.010</pub-id><pub-id pub-id-type="pmid">15033129</pub-id></element-citation></ref></ref-list></back></article>